Tango Therapeutics, Inc. (TNGX) Stock Price & Analysis
Tango Therapeutics, Inc. (TNGX) rose 2.04% to USD 31.56 as of June 10, 2026 at 02:39 UTC, according to Nexqual real-time market data.
TNGX last closed at USD 30.93; the session ranged USD 29.41–32.79 on volume of 7,133,450 shares. Market capitalization is $4.57B, with a 52-week range of USD 4.32–32.79 (NGM). Source: Nexqual, June 10, 2026 at 02:39 UTC.
Key Statistics (as of June 10, 2026 at 02:39 UTC)
| Price | USD 31.56 |
|---|---|
| Change | ▲ 2.04% (up) |
| Previous Close | USD 30.93 |
| Open | USD 32.19 |
| Day Range | USD 29.41 – 32.79 |
| 52-Week Range | USD 4.32 – 32.79 |
| Volume | 7,133,450 shares |
| Market Cap | $4.57B |
| Exchange | NGM |
Technical Analysis (TNGX)
Nexqual's technical model rates TNGX "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 02:39 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 68.05 (neutral) |
| vs SMA50 | Above (USD 22.93) |
| MACD | 1.08 (positive) |
Analyst Ratings (TNGX)
Wall Street analysts rate TNGX "Strong Buy" based on 11 analysts, with a mean price target of USD 36.91 (range USD 24–69), per Nexqual as of June 10, 2026 at 02:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 36.91 |
| High Target | USD 69 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 10 / 2 / 0 |
Earnings (TNGX)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.33 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.32 vs est -0.31 ▼ miss |
| 2025-12-31 | USD -0.29 vs est -0.33 ▲ beat |
| 2025-09-30 | USD 0.13 vs est -0.07 ▲ beat |
| 2025-06-30 | USD -0.35 vs est -0.34 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Financials & Fundamentals (TNGX)
| Total Revenue | $56.99M |
|---|---|
| Gross Margin | -126.80% |
| Operating Margin | -206.22% |
| Profit Margin | -188.15% |
| ROE | -38.42% |
| Debt / Equity | 8.38 |
| Current Ratio | 27.38 |
| Total Cash | $379.84M |
| Total Debt | $32.79M |
| Free Cash Flow | $-68.23M |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Financial Health Score (TNGX)
Nexqual rates Tango Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 02:39 UTC.
| Growth | Strong — Revenue +48% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $380M cash vs $33M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$68M, burning cash |
| Efficiency | Critical — ROE -38%, ROA -20.7% |
Ownership (TNGX)
| Insider Ownership | +1.31% |
|---|---|
| Institutional Ownership | +127.77% |
| Shares Outstanding | 144.65M |
| Float | 69.60M |
| Short % of Float | +23.46% |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Leadership (TNGX)
Tango Therapeutics, Inc. is led by Malte Peters (age 63), President, CEO & Director, per Nexqual as of June 10, 2026 at 02:39 UTC.
| President, CEO & Director | Malte Peters (age 63) |
|---|---|
| President of Research & Development | Adam S. Crystal (age 48) |
| Chief Financial Officer | Matthew Gall (age 48) |
| Chief Scientific Officer | Jannik N. Andersen |
| Vice President of Legal & Corporate Secretary | Julie Fogarty |
Major Backers & Investors (TNGX)
Notable institutional backers of Tango Therapeutics, Inc. include RTW Investments LP, Adage Capital Partners GP L.L.C., Boxer Capital Management, LLC, according to Nexqual as of June 10, 2026 at 02:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 9.2% |
| Adage Capital Partners GP L.L.C. | 8.86% |
| Boxer Capital Management, LLC | 7.52% |
| TCG Crossover Management, LLC | 7.28% |
| FMR, LLC | 6.85% |
| Farallon Capital Management LLC | 6.29% |
| Woodline Partners LP | 5.53% |
| Nextech Invest, Ltd. | 5.02% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.98% |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
From Tango Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
- The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
- It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ERAS | Erasca, Inc. | USD 13.41 | ▲ 12.03% |
| TYRA | Tyra Biosciences, Inc. | USD 25.94 | ▼ 2.63% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 16.61 | ▲ 1.47% |
| RLAY | Relay Therapeutics, Inc. | USD 14.09 | ▲ 4.22% |
| TVTX | Travere Therapeutics, Inc. | USD 48.57 | ▲ 6.02% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:39 UTC. This page is informational and not investment advice.